Wall Street Zen Upgrades TScan Therapeutics (NASDAQ:TCRX) to "Hold"

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

TCRX has been the subject of a number of other reports. Morgan Stanley reissued an "overweight" rating and issued a $10.00 target price on shares of TScan Therapeutics in a research report on Friday, March 14th. Wedbush reaffirmed an "outperform" rating and set a $7.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, May 6th. HC Wainwright dropped their price target on TScan Therapeutics from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $9.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, April 8th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $7.80.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX traded down $0.16 during trading hours on Friday, hitting $1.77. 278,091 shares of the stock were exchanged, compared to its average volume of 409,643. The company's fifty day simple moving average is $1.50 and its two-hundred day simple moving average is $1.82. The company has a market cap of $99.88 million, a PE ratio of -1.61 and a beta of 0.97. TScan Therapeutics has a 1-year low of $1.02 and a 1-year high of $7.89. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.55 and a current ratio of 8.55.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative return on equity of 55.76% and a negative net margin of 2,974.08%. The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. On average, sell-side analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Insider Activity at TScan Therapeutics

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 1,200,000 shares of TScan Therapeutics stock in a transaction dated Tuesday, May 20th. The stock was acquired at an average cost of $1.20 per share, with a total value of $1,440,000.00. Following the purchase, the insider directly owned 7,946,141 shares in the company, valued at $9,535,369.20. This represents a 17.79% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 4.35% of the stock is owned by insiders.

Hedge Funds Weigh In On TScan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. Lynx1 Capital Management LP lifted its holdings in TScan Therapeutics by 2.5% during the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after buying an additional 132,747 shares in the last quarter. BVF Inc. IL increased its stake in shares of TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company's stock worth $6,747,000 after purchasing an additional 1,900,000 shares in the last quarter. Checkpoint Capital L.P. raised its position in shares of TScan Therapeutics by 14.9% in the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company's stock valued at $2,784,000 after buying an additional 261,663 shares during the last quarter. Aberdeen Group plc increased its position in TScan Therapeutics by 0.9% during the first quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after purchasing an additional 7,744 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of TScan Therapeutics by 108.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock worth $851,000 after buying an additional 145,731 shares during the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.